StocksFundsScreenerSectorsWatchlists
IART

IART - Integra LifeSciences Holdings Corp Stock Price, Fair Value and News

33.15USD-0.93 (-2.73%)Market Closed

Market Summary

IART
USD33.15-0.93
Market Closed
-2.73%

IART Alerts

  • 1 major insider sales recently.

IART Stock Price

View Fullscreen

IART RSI Chart

IART Valuation

Market Cap

2.6B

Price/Earnings (Trailing)

38.28

Price/Sales (Trailing)

1.68

EV/EBITDA

21.8

Price/Free Cashflow

35.48

IART Price/Sales (Trailing)

IART Profitability

EBT Margin

5.26%

Return on Equity

4.27%

Return on Assets

1.79%

Free Cashflow Yield

2.82%

IART Fundamentals

IART Revenue

Revenue (TTM)

1.5B

Rev. Growth (Yr)

-0.25%

Rev. Growth (Qtr)

3.82%

IART Earnings

Earnings (TTM)

67.7M

Earnings Growth (Yr)

-62.54%

Earnings Growth (Qtr)

1.73%

Breaking Down IART Revenue

Last 7 days

-1.9%

Last 30 days

-7.6%

Last 90 days

-22.8%

Trailing 12 Months

-42.5%

How does IART drawdown profile look like?

IART Financial Health

Current Ratio

3.45

Debt/Equity

0.36

Debt/Cashflow

0.25

IART Investor Care

Buy Backs (1Y)

4.18%

Diluted EPS (TTM)

0.84

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20231.6B1.5B1.5B1.5B
20221.6B1.6B1.6B1.6B
20211.4B1.5B1.5B1.5B
20201.5B1.4B1.4B1.4B
20191.5B1.5B1.5B1.5B
20181.3B1.4B1.5B1.5B
20171.0B1.0B1.1B1.2B
2016917.0M953.6M977.6M992.1M
2015816.2M831.8M860.6M882.7M
2014822.6M814.1M798.4M796.7M
2013831.3M826.7M829.9M836.2M
2012795.2M812.1M820.0M830.9M
2011740.4M755.1M770.7M780.1M
2010694.2M707.1M721.5M732.1M
20090663.9M673.2M682.5M
2008000654.6M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Integra LifeSciences Holdings Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 12, 2024
schwartz eric
sold (taxes)
-51,595
35.88
-1,438
evp, chief legal officer & sec
Mar 12, 2024
davis robert t. jr.
sold (taxes)
-72,621
35.88
-2,024
evp & president, tt
Mar 12, 2024
mcbreen michael j.
sold (taxes)
-72,190
35.88
-2,012
evp & president, css
Mar 12, 2024
mosebrook jeffrey
sold (taxes)
-12,450
35.88
-347
svp, fin & princ acct officer
Mar 11, 2024
schwartz eric
acquired
-
-
16,028
evp, chief legal officer & sec
Mar 11, 2024
de witte jan
sold (taxes)
-7,425
36.22
-205
president & ceo
Mar 11, 2024
veillon-berteloot chantal
acquired
-
-
11,758
evp & chro
Mar 11, 2024
davis robert t. jr.
sold (taxes)
-87,290
36.22
-2,410
evp & president, tt
Mar 11, 2024
davis robert t. jr.
acquired
-
-
20,283
evp & president, tt
Mar 11, 2024
mcbreen michael j.
sold (taxes)
-142,055
36.22
-3,922
evp & president, css

1–10 of 50

Which funds bought or sold IART recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 09, 2024
MATHER GROUP, LLC.
new
-
3,266
3,266
-%
Apr 09, 2024
MASSMUTUAL TRUST CO FSB/ADV
added
11.48
-246
2,411
-%
Apr 09, 2024
Rise Advisors, LLC
added
1,026
10,675
11,982
0.01%
Apr 09, 2024
Alaska Permanent Fund Corp
new
-
456,809
456,809
0.01%
Apr 05, 2024
CWM, LLC
added
0.6
-6,000
30,000
-%
Apr 05, 2024
GAMMA Investing LLC
added
81.4
1,039
2,765
-%
Apr 03, 2024
Versant Capital Management, Inc
sold off
-100
-3,745
-
-%
Mar 27, 2024
NOMURA HOLDINGS INC
added
20.27
724,358
2,683,200
0.01%
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
reduced
-2.22
60,621
587,795
-%
Mar 11, 2024
VANGUARD GROUP INC
reduced
-2.05
31,972,300
305,407,000
0.01%

1–10 of 43

Are Funds Buying or Selling IART?

Are funds buying IART calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own IART
No. of Funds

Unveiling Integra LifeSciences Holdings Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
champlain investment partners, llc
3.12%
2,435,957
SC 13G/A
Feb 13, 2024
vanguard group inc
8.97%
7,012,793
SC 13G/A
Feb 09, 2024
wellington management group llp
4.28%
3,349,368
SC 13G/A
Feb 09, 2024
morgan stanley
5.9%
4,634,346
SC 13G/A
Feb 09, 2024
capital research global investors
5.5%
4,297,326
SC 13G
Jan 25, 2024
blackrock inc.
8.5%
6,641,845
SC 13G/A
Feb 14, 2023
tru st partnership, l.p.
10.20%
8,515,930
SC 13G/A
Feb 13, 2023
champlain investment partners, llc
6.30%
5,259,524
SC 13G/A
Feb 09, 2023
morgan stanley
6.8%
5,681,483
SC 13G/A
Feb 09, 2023
vanguard group inc
8.56%
7,147,759
SC 13G/A

Recent SEC filings of Integra LifeSciences Holdings Corp

View All Filings
Date Filed Form Type Document
Apr 04, 2024
ARS
ARS
Apr 04, 2024
DEF 14A
DEF 14A
Mar 25, 2024
PRE 14A
PRE 14A
Mar 13, 2024
4
Insider Trading
Mar 13, 2024
4
Insider Trading
Mar 13, 2024
4
Insider Trading
Mar 13, 2024
4
Insider Trading
Mar 13, 2024
4
Insider Trading
Mar 13, 2024
4
Insider Trading
Mar 13, 2024
4
Insider Trading

Peers (Alternatives to Integra LifeSciences Holdings Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
193.3B
40.1B
-7.74% 9.17%
33.78
4.82
-8.12% -17.45%
69.5B
19.5B
1.13% -5.26%
55.32
3.56
4.02% -22.04%
24.4B
3.9B
4.50% -2.28%
54.79
6.31
3.42% 23.09%
21.4B
14.8B
-1.84% -1.34%
8.05
1.44
2.12% 209.17%
MID-CAP
9.2B
12.3B
-3.51% -12.61%
22.18
0.75
-2.44% -22.68%
9.2B
3.5B
-2.27% 17.56%
32.3
2.63
4.97% 18.89%
9.1B
2.7B
-7.47% -34.56%
-14.3
3.41
-4.68% 82.43%
6.6B
4.0B
-4.70% -20.93%
-49.38
1.68
1.10% 85.84%
3.5B
366.4M
0.09% 23.27%
-569.03
9.43
33.86% 89.83%
2.3B
6.6B
-4.53% -3.52%
11.92
0.35
2.78% -0.87%
SMALL-CAP
1.3B
3.2B
-7.20% -16.80%
-1.97
0.42
7.73% -1066.14%
380.3M
166.7M
-0.70% -5.95%
-4.6
2.28
6.67% -456.34%
272.8M
324.0M
24.04% -26.14%
-1.42
0.84
-3.19% -337.41%
53.7M
52.3M
-9.88% -51.41%
-2.87
1.03
17.61% 19.28%
4.1M
3.7M
-7.69% 310.53%
-0.33
1.09
5.77% 8.23%

Integra LifeSciences Holdings Corp News

Latest updates
MarketBeat13 hours ago
Yahoo Finance UK09 Apr 202412:41 pm

Integra LifeSciences Holdings Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue3.8%397382381381398385398377406387390360389370259354395379384360383
Costs and Expenses1.5%361356369344330320338330347330338329336313245327359400338327349
  S&GA Expenses0.7%163162165167152144161160162156163157162150116166174173165175177
  R&D Expenses---------------15.0021.00-19.0018.0018.0020.00
EBITDA Margin-20.6%0.09*0.11*0.21*0.24*0.24*0.23*0.23*0.22*0.25*0.24*0.25*0.24*---------
Interest Expenses5.3%14.0013.0012.0012.0013.0013.0012.0012.0012.0012.0013.0013.0017.0021.0016.0018.0013.0014.0013.0013.0014.00
Income Taxes1116.2%9.00-0.89-0.366.0011.009.007.006.006.008.0010.0022.00-53.839.002.002.0011.000.007.00-7.93-0.62
Earnings Before Taxes55.1%29.0019.004.0030.0064.0059.0052.0039.0052.0051.0045.0067.0039.0042.002.0011.0026.00-27.5136.0025.0025.00
EBT Margin-30.3%0.05*0.08*0.10*0.13*0.14*0.13*0.12*0.12*0.14*0.13*0.13*0.11*---------
Net Income1.7%20.0019.004.0024.0053.0050.0045.0033.0045.0043.0035.0045.0093.0032.00-0.379.0015.00-27.6130.0033.0025.00
Net Income Margin-32.8%0.04*0.07*0.08*0.11*0.12*0.11*0.11*0.10*0.11*0.14*0.14*0.12*---------
Free Cashflow149.9%34.0014.0013.0012.0071.0059.0057.0035.0042.0075.0085.0062.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets1.1%3,7823,7393,7783,7423,8903,8073,7533,6723,7823,7743,7133,7423,6153,4543,3923,4483,3033,3473,2903,2063,108
  Current Assets3.0%1,0581,0271,0511,0291,1611,1961,1371,0661,1541,1041,0321,0391,2371,1529661,009858884869823775
    Cash Equivalents1.0%276274309307457512447407513470397409470396361358199208176157139
  Inventory6.4%390366354351325311320328317327324328310308359338316303297287280
  Net PPE6.7%340319318315311301302309312294296296288294334336337319316306300
  Goodwill1.9%1,0551,0361,0431,0421,0399789901,0091,0131,01294.001,010932920956952954945927923926
Liabilities1.6%2,1942,1602,0942,0672,0852,0832,0922,0572,0982,1432,1382,2122,1002,0562,0432,1061,8871,9621,8691,8091,732
  Current Liabilities-13.7%307356377282321304296316340333319412401255212246331303315288263
  Long Term Debt0.1%570570569568567567566565564564563562-2.50470465460-----
    LT Debt, Non Current0.1%570570569568567567566565564564563562-2.50470465460-----
Shareholder's Equity0.5%1,5881,5791,6831,6751,8041,7241,6611,6151,6851,6321,5751,5291,5151,3981,3491,3421,4171,3851,4211,3971,376
  Retained Earnings2.1%947927908903879826776731699653610575532440407408399383411381348
  Additional Paid-In Capital3.2%1,3021,2621,2841,2451,2771,2681,2601,2671,2651,2591,2491,2321,2911,2851,2791,2401,2141,2091,1981,1921,193
Shares Outstanding0.5%80.0080.0081.0082.0083.0083.0083.0084.0085.0085.0085.0085.00---------
Float---3,257---3,916---4,969---3,370---3,946--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations119.5%59.0027.0028.0026.0085.0068.0066.0044.0069.0083.0091.0069.0080.0070.0033.0021.0089.0064.0049.0029.0043.00
  Share Based Compensation6.1%6.005.005.004.006.009.007.006.006.008.0016.006.005.005.005.004.006.006.006.004.005.00
Cashflow From Investing-643.5%-57.23-7.70-15.55-13.70-54.8215.00-4.50-14.07-27.48-8.47-7.92-117-35.92-6.72-3.95-21.48-20.61-108-17.41-15.81-25.33
Cashflow From Financing86.1%-6.89-49.66-10.69-162-97.70-7.64-13.15-1331.002.00-97.47-3.0121.00-33.05-28.55162-81.9981.00-13.195.00-84.05
  Buy Backs-101.0%-1.22126-151---125-----4.00-92.00-----

IART Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Total revenue, net$ 1,541,573$ 1,557,666$ 1,542,448
Costs and expenses:   
Cost of goods sold656,838587,355597,808
Research and development104,192101,19393,051
Selling, general and administrative656,641616,316637,445
Intangible asset amortization12,37613,88216,914
Total costs and expenses1,430,0471,318,7461,345,218
Operating income111,526238,920197,230
Interest income17,20211,9176,737
Interest expense(51,377)(49,594)(50,395)
Gain from sale of businesses064441,798
Other income, net3,71812,00719,307
Income before income taxes81,069213,894214,677
Provision for income taxes13,32833,34445,602
Net income$ 67,741$ 180,550$ 169,075
Net income per share   
Basic (in dollars per share)$ 0.85$ 2.18$ 2.00
Diluted (in dollars per share)$ 0.84$ 2.16$ 1.98
Weighted average common shares outstanding (See Note 13):   
Basic (in shares)80,08982,99784,698
Diluted (in shares)80,33783,51685,485

IART Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current Assets:  
Cash and cash equivalents$ 276,402$ 456,661
Short-term investments32,6940
Trade accounts receivable, net of allowances of $4,879 and $4,304259,327263,465
Inventories, net389,608324,583
Prepaid Expenses67,36285,757
Other Current Assets32,64331,032
Total current assets1,058,0361,161,498
Property, plant and equipment, net340,199311,302
Right of use asset - operating leases156,184148,284
Intangible assets, net1,067,8331,126,609
Goodwill1,055,4621,038,881
Deferred tax assets, net46,08045,994
Other assets58,19457,190
Total assets3,781,9883,889,758
Current Liabilities:  
Current portion of borrowings under senior credit facility14,53138,125
Current portion of lease liability - operating leases15,28414,624
Accounts payable, trade92,326102,100
Contract liabilities8,5407,253
Accrued compensation75,45578,771
Accrued expenses and other current liabilities100,84480,033
Total current liabilities306,980320,906
Long-term borrowings under senior credit facility825,563733,149
Long-term borrowings under securitization facility89,200104,700
Long-term convertible securities570,255567,341
Lease liability - operating leases166,849157,420
Deferred tax liabilities35,31763,338
Other liabilities199,940138,501
Total liabilities2,194,1042,085,355
Stockholders’ Equity:  
Preferred Stock; no par value; 15,000 authorized shares; none outstanding00
Common stock; $0.01 par value; 240,000 authorized shares; 90,920 and 90,477 issued at December 31, 2023 and 2022, respectively909905
Additional paid-in capital1,302,4841,276,977
Treasury stock, at cost; 12,751 and 6,823 shares at December 31, 2023 and 2022, respectively(647,262)(362,862)
Accumulated other comprehensive income (loss)(15,106)10,265
Retained earnings946,859879,118
Total stockholders’ equity1,587,8841,804,403
Total liabilities and stockholders’ equity$ 3,781,988$ 3,889,758
IART
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
 CEO
 WEBSITEintegralife.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES3722

Integra LifeSciences Holdings Corp Frequently Asked Questions


What is the ticker symbol for Integra LifeSciences Holdings Corp? What does IART stand for in stocks?

IART is the stock ticker symbol of Integra LifeSciences Holdings Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Integra LifeSciences Holdings Corp (IART)?

As of Thu Apr 11 2024, market cap of Integra LifeSciences Holdings Corp is 2.59 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IART stock?

You can check IART's fair value in chart for subscribers.

What is the fair value of IART stock?

You can check IART's fair value in chart for subscribers. The fair value of Integra LifeSciences Holdings Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Integra LifeSciences Holdings Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IART so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Integra LifeSciences Holdings Corp a good stock to buy?

The fair value guage provides a quick view whether IART is over valued or under valued. Whether Integra LifeSciences Holdings Corp is cheap or expensive depends on the assumptions which impact Integra LifeSciences Holdings Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IART.

What is Integra LifeSciences Holdings Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 11 2024, IART's PE ratio (Price to Earnings) is 38.28 and Price to Sales (PS) ratio is 1.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IART PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Integra LifeSciences Holdings Corp's stock?

In the past 10 years, Integra LifeSciences Holdings Corp has provided 0.052 (multiply by 100 for percentage) rate of return.